Related Experiment Videos
Alterations in the regulatory pathway involving p16, pRb and cdk4 in human chondrosarcoma
1Department of Clinical Chemistry and Transfusion Medicine, Research Center for Endocrinology and Metabolism, Institution of Laboratory Medicine, Sahlgrenska University Hospital, Göteborg, Sweden.
Abstract:
The G1 regulatory pathway involving p16, pRb and cdk4 in the cell cycle has been investigated in human chondrosarcoma. The protein expression of p16, pRb and cdk4 was analyzed by Western blot in cultured cells from eight chondrosarcomas and in two chondrosarcoma cell lines. Both cell lines and one other sample were negative for p16. Moreover, one of the cell lines was pRb-negative and showed a high expression of cdk4 as well. In the other cell line and in three other samples pRb of expected size were detected in addition to a shorter form of the protein. To further investigate the reasons for down-regulation of the p16 protein, the p16-coding gene CDKN2 was analyzed by polymerase chain reaction (PCR), methyl-specific PCR (MSP) and sequencing in all tumor samples as well as in corresponding tumor tissues from three of the samples. The p16-negative samples were all found to have homozygous deletion of CDKN2. Another sample showed partial gene methylation and a heterozygous position in codon 148 was detected in one sample. The same base substitution was also found in two of the tissue samples. Finally, cytogenetic analysis of the samples with homozygously deleted CDKN2 revealed multiple structural abnormalities in all three cases. In conclusion, the p16/pRb/cdk4 pathway may play an important role in the pathogenesis of some chondrosarcomas.
Insights
The p16/pRb/cdk4 cell cycle pathway is altered in human chondrosarcoma. Homozygous deletion of the CDKN2 gene, encoding p16, was found in p16-negative tumors, suggesting its role in chondrosarcoma development.
Area of Science:
- Oncology
- Molecular Biology
- Cell Cycle Regulation
Background:
- The G1 regulatory pathway involving p16, pRb, and cdk4 is crucial for cell cycle control.
- Dysregulation of this pathway is implicated in various cancers.
- Its role in human chondrosarcoma pathogenesis requires further investigation.
Purpose of the Study:
- To investigate the G1 regulatory pathway (p16/pRb/cdk4) in human chondrosarcoma.
- To analyze protein expression and genetic alterations of key pathway components.
- To determine the potential role of this pathway in chondrosarcoma development.
Main Methods:
- Western blot analysis of p16, pRb, and cdk4 protein expression in chondrosarcoma cell lines and primary tumors.
- Polymerase chain reaction (PCR), methyl-specific PCR (MSP), and sequencing of the CDKN2 gene.
- Cytogenetic analysis of tumor samples.
Main Results:
- p16 protein was negative in several cell lines and tumor samples.
- Homozygous deletion of the CDKN2 gene was identified in p16-negative samples.
- Aberrant pRb forms and high cdk4 expression were observed in some cases.
- Cytogenetic analysis revealed multiple structural abnormalities in tumors with CDKN2 deletion.
Conclusions:
- The p16/pRb/cdk4 pathway is frequently altered in human chondrosarcoma.
- Homozygous deletion of CDKN2 is a significant mechanism for p16 loss in these tumors.
- These alterations suggest the pathway's important role in chondrosarcoma pathogenesis.